Pipeline

Debiopharm’s projects cover all molecule type proteins, peptides, small molecules

Oncology

Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
_ Debio 4326
Central Precocious Puberty – 12M GnRH agonist analogue
12M GnRH agonist analogue
_ Debio 4126
Acromegaly – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 0228
Oncology – CAIX-targeted radiotherapy
CAIX-targeted radiotherapy
_ Debio 4228
Oncology – Undisclosed
Undisclosed
_ Debio 0432
Oncology – USP1 inhibitor
USP1 inhibitor
_ Debio 4028
Oncology – IAP antagonist
IAP antagonist
Merck
_ Debio 0532
Oncology – Anti-HER3 ADC/ Multilink
Anti-HER3 ADC/ Multilink
Repare: Repare Therapeutics
Merck: Merck KGaA

Enabling Technologies

Program Indication Mode of Action
Prototype Preclinical Phase I Phase II Phase III
_ Multilink™
Multidrug linker platform – Cleavable linker for ADC, applicable to different payloads
Cleavable linker for ADC, applicable to different payloads
Genome/Ubix
_ AbYlink™
Diagnostic and therapeutic antibody conjugation technology – Antibody conjugation
Antibody conjugation
Genome: Genome & Company
Ubix: Ubix Therapeutics

Infectious disease

Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
_ Debio 1454/M
GI disorders – microbiome remodeling
microbiome remodeling
_ FibroTrap™ (Debio 1561)
Infectious diseases – Sample prep. Technology
Sample prep. Technology
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X grant: CARB-X

Our commercialized products

  • Triptorelin

    Triptorelin is a gonadotropin releasing hormone (GnRH) agonist

    Discover
  • Oxaliplatin

    A major advance in the history of cancer treatment

    Discover